PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:PBH • US74112D1019
64.43 USD
-1.01 (-1.54%)
At close: Feb 3, 2026
64.43 USD
0 (0%)
After Hours: 2/3/2026, 8:04:00 PM
Overall PBH gets a fundamental rating of 6 out of 10. We evaluated PBH against 191 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year PBH was profitable.
- PBH had a positive operating cash flow in the past year.
- PBH had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of PBH (5.83%) is better than 86.91% of its industry peers.
- PBH has a Return On Equity of 11.00%. This is amongst the best in the industry. PBH outperforms 85.34% of its industry peers.
- PBH has a Return On Invested Capital of 7.88%. This is amongst the best in the industry. PBH outperforms 85.86% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
- PBH has a Profit Margin of 18.09%. This is amongst the best in the industry. PBH outperforms 90.05% of its industry peers.
- In the last couple of years the Profit Margin of PBH has grown nicely.
- The Operating Margin of PBH (31.00%) is better than 94.24% of its industry peers.
- In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
- PBH's Gross Margin of 56.10% is fine compared to the rest of the industry. PBH outperforms 68.06% of its industry peers.
- PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
- PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, PBH has less shares outstanding
- The number of shares outstanding for PBH has been reduced compared to 5 years ago.
- Compared to 1 year ago, PBH has an improved debt to assets ratio.
2.2 Solvency
- PBH has an Altman-Z score of 2.60. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a decent Altman-Z score value of 2.60, PBH is doing good in the industry, outperforming 65.44% of the companies in the same industry.
- PBH has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as PBH would need 3.97 years to pay back of all of its debts.
- PBH has a Debt to FCF ratio of 3.97. This is amongst the best in the industry. PBH outperforms 86.39% of its industry peers.
- A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
- The Debt to Equity ratio of PBH (0.55) is worse than 65.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.6 |
ROIC/WACC0.88
WACC8.98%
2.3 Liquidity
- PBH has a Current Ratio of 3.70. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
- PBH has a Current ratio of 3.70. This is comparable to the rest of the industry: PBH outperforms 57.07% of its industry peers.
- PBH has a Quick Ratio of 2.51. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.51, PBH perfoms like the industry average, outperforming 51.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
- PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
- The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
- The Revenue has decreased by -0.02% in the past year.
- Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
- PBH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.13% yearly.
- The Revenue is expected to grow by 1.15% on average over the next years.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- PBH is valuated correctly with a Price/Earnings ratio of 14.13.
- 86.91% of the companies in the same industry are more expensive than PBH, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 28.18. PBH is valued slightly cheaper when compared to this.
- The Price/Forward Earnings ratio is 13.16, which indicates a correct valuation of PBH.
- PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 84.82% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of PBH to the average of the S&P500 Index (25.51), we can say PBH is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.13 | ||
| Fwd PE | 13.16 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaply inside the industry as 87.96% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 89.01% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.13 | ||
| EV/EBITDA | 10.69 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)8.61
PEG (5Y)1.59
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
- PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
64.43
-1.01 (-1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-05 2026-02-05/bmo
Inst Owners108.83%
Inst Owner Change-0.18%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap3.10B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (22.69%)
Short Float %4.37%
Short Ratio5.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)0%
PT rev (3m)-4.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.8%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.13 | ||
| Fwd PE | 13.16 | ||
| P/S | 2.79 | ||
| P/FCF | 12.13 | ||
| P/OCF | 11.76 | ||
| P/B | 1.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.69 |
EPS(TTM)4.56
EY7.08%
EPS(NY)4.9
Fwd EY7.6%
FCF(TTM)5.31
FCFY8.25%
OCF(TTM)5.48
OCFY8.5%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.61
PEG (5Y)1.59
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.6 |
F-Score7
WACC8.98%
ROIC/WACC0.88
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.